目的 探讨枫蓼肠胃康颗粒联合枸橼酸铋雷尼替丁三联疗法治疗慢性胃炎的临床疗效。方法 选取2018年1月-2019年3月在巴中市中心医院就诊的130例慢性胃炎患者作为研究对象，将全部患者以随机数字表法随机分为对照组和治疗组，每组各65例。对照组给予枸橼酸铋雷尼替丁三联治疗，口服枸橼酸铋雷尼替丁胶囊，0.4 g/次，2次/d；口服阿莫西林胶囊，0.5 g/次，2次/d；口服甲硝唑片，0.4 g/次，3次/d。治疗组患者在对照组基础上温水冲服枫蓼肠胃康颗粒，8 g/次，3次/d。两组患者连续治疗15 d。观察两组的临床疗效，比较两组的临床症状改善情况、血清炎症因子水平、激素水平、幽门螺杆菌感染转阴情况。结果 治疗后，对照组和治疗组的总有效率分别为81.54%、93.85%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组的嗳气消失时间、烧灼反酸消失时间、上腹疼痛消失时间明显短于对照组，差异有统计学意义（P<0.05）。治疗后，两组C反应蛋白（CRP）、白细胞介素-1β（IL-1β）、白细胞介素-17（IL-17）、白细胞介素-8（IL-8）水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组的血清炎症因子水平明显低于对照组，差异有统计学意义（P<0.05）。治疗后，两组胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ水平明显降低，胃泌素、胃动素水平明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组的激素水平明显优于对照组，差异有统计学意义（P<0.05）。治疗后1个月，对照组和治疗组的转阴率分别为61.54%、78.46%，两组比较差异有统计学意义（P<0.05）。结论 枫蓼肠胃康颗粒联合枸橼酸铋雷尼替丁三联疗法治疗慢性胃炎具有较好的临床疗效，可改善临床症状，减轻炎症反应，调节胃肠激素的分泌，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Fengliao Changweikang Granules combined with ranitidine bismuth citrate triple therapy in treatment of chronic gastritis. Methods Patients (130 cases) with chronic gastritis in Bazhong Central Hospital from January 2018 to March 2019 were randomly divided into control and treatment groups, and each group had 65 cases. Patients in the control group were given ranitidine bismuth citrate triple therapy:patients were po administered with Ranitidine Bismuth Citrate Capsules, 0.4 g/time, twice daily; and patients were po administered with Amoxicllin Capsules, 0.5 g/time, twice daily; and patients were po administered with Metronidazole Tablets, 0.4 g/time, three times daily. Patients in the treatment group were po administered with Fengliao Changweikang Granules on the basis of the control group, 8 g/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacies were evaluated, and the improvement of clinical symptoms, the serum levels of inflammatory factors, the hormone levels, and the negative conversion rates of helicobacter pylori infection in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.54% and 93.85%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearance times of belching, burning and acid regurgitation, and upper abdominal pain in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, the levels of CRP, IL-1β, IL-17, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of pepsinogen Ⅰ and pepsinogen Ⅱ in two groups were significantly increased, but the levels of gastrin and motilin in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the hormone levels, in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). One month after treatment, the negative conversion rate of helicobacter pylori infection in the control and treatment groups were 61.54% and 78.46%, respectively, and there was difference between two groups (P<0.05). Conclusion Fengliao Changweikang Granules combined with ranitidine bismuth citrate triple therapy has clinical curative effect in treatment of chronic gastritis, can improve clinical symptoms, alleviate inflammation, and regulate the secretion of gastrointestinal hormones, which has a certain clinical application value.